Search Axplora

Home / News / Axplora’s sustainability strategy substantiated by SBTi as company accelerates action across its manufacturing network

Axplora’s sustainability strategy substantiated by SBTi as company accelerates action across its manufacturing network

5 August 26 • 4 min read

Share this post

Link copied to clipboard!
  • Science Based Targets initiative (SBTi) validation provides independent confirmation of Axplora’s emissions-reduction targets. 
  • Targets reinforce Axplora’s commitment to helping customers build responsible, transparent and resilient pharmaceutical supply chains. 
  • Axplora’s ActNow 2030 initiative commits to reducing Scope 1 and 2 emissions by 42% and Scope 3 emissions by 25% by 2030. 

July 2026 – Axplora, a global manufacturing partner for small-molecule active pharmaceutical ingredients (APIs) and antibody-drug conjugates (ADCs), today announced that its greenhouse gas emissions-reduction targets have been validated by the Science Based Targets initiative (SBTi).  

The certification provides independent confirmation of Axplora’s long-term sustainability strategy and strengthens the framework behind its ActNow 2030 programme. Rather than marking the start of its sustainability journey, it recognises a strategy that is already being embedded across the company’s manufacturing network through investments, process development, supplier partnerships and day-to-day operations. 

The verification follows a series of recent sustainability milestones across the business. Last month, four of Axplora’s European CDMO manufacturing sites were recognised by EcoVadis, with Leverkusen awarded Platinum, Le Mans Gold, and Pompey and Chasse-sur-Rhône Silver. Together, these independent assessments reflect both the progress already being made across the business and the long-term framework guiding Axplora’s sustainability strategy. 

By 2030, Axplora has committed to: 

  • Reducing absolute Scope 1 and Scope 2 greenhouse gas emissions by 42% from a 2023 baseline. 
  • Reducing absolute Scope 3 greenhouse gas emissions by 25% from a 2023 baseline. 

The targets cover emissions from Axplora’s operations and purchased energy, as well as value-chain activities including purchased goods and services, transportation, business travel and waste. 

Sustainability is becoming an increasingly important factor in supplier selection across the pharmaceutical industry, particularly among leading global pharmaceutical companies. SBTi validation gives customers independent assurance that Axplora has a credible, measurable and science-based approach to reducing emissions while supporting transparent, resilient supply chains. 

This shift is already shaping how long-term manufacturing partnerships are being formed. For example, a recently agreed strategic partnership between Axplora and a leading European pharmaceutical company includes sustainability performance alongside quality, delivery and innovation as one of the foundations of the relationship. The customer’s ambitious emissions-reduction objectives helped shape the collaboration, demonstrating how ESG has become a strategic differentiator rather than simply a compliance requirement. 

Anant Barbadikar, Co-President of PharmaZell and Executive Management Committee member responsible for ESG, said: 

“Our focus now is execution. By making targeted improvements across our sites and working closely with employees, customers and suppliers, we can turn these commitments into practical action and give customers greater confidence in the manufacturing partner supporting their medicines.” 

Françoise Durand-Rivoire, Global Head of ESG & Public Affairs at Axplora, added: 

“SBTi validation provides independent confirmation that our emissions-reduction plans are built on a recognised scientific framework. More importantly, it gives us a clear roadmap for embedding emissions reduction into investment decisions, manufacturing processes, procurement and supplier collaboration across the business. 

“This is about more than setting targets. Measuring our impact more precisely helps us identify where processes can be improved, resources used more effectively and risks addressed earlier – strengthening both our operations and the resilience of our customers’ supply chains.” 

The validation is an important milestone within ActNow 2030, Axplora’s company-wide sustainability programme. To deliver its commitments, the company is embedding emissions reduction into investment decisions, process development, procurement and daily operations across its sites and functions. Axplora is also working closely with suppliers to reduce value-chain emissions and strengthen responsible sourcing. 

This coordinated approach includes using energy and materials more efficiently, reducing waste and optimising manufacturing processes—lowering environmental impact while helping customer programmes progress reliably and efficiently. 

Through ActNow 2030, Axplora is combining scientific expertise, responsible manufacturing and close collaboration to help customers build more resilient pharmaceutical supply chains while reducing environmental impact. SBTi validation provides independent confirmation that the company is delivering against a clear, measurable and science-based roadmap for long-term sustainable growth. 

About Axplora

Axplora is a trusted manufacturing partner to over 900 of the world’s leading pharmaceutical and biotech companies, formed from the integration of PharmaZell, Farmabios, and Novasep CDMO —three industry leaders with decades of experience in pharmaceutical manufacturing. Axplora delivers high-quality, reliable, and sustainable solutions across the pharmaceutical value chain.

With deep capabilities in complex chemistry and industrial manufacturing combined with an agile, explorer’s mindset, Axplora supports pharmaceutical and biotech companies in developing and producing life-changing therapies. PharmaZell and Farmabios are renowned for their expertise in active pharmaceutical ingredients (APIs), highly potent compounds, and regulatory excellence, while Novasep CDMO is a leader in small molecule and antibody-drug conjugates (ADCs) manufacturing while being a pioneer in purification technologies.

Axplora operates 9 API manufacturing sites across Europe and India, providing multi-site capacity to partners worldwide.

For more information, visit www.axplora.com

Press contacts:

Will Frost (UK/US)
Phone: +44 (0)7799652421

Thomas Goldberg (Europe)
Phone: +33 (0)6 03 78 55 63

press@axplora.com
axplora.com

Share this post

Link copied to clipboard!

Latest news

News

November 03, 2026

Axplora partners with Abionyx to support development of CER-001

Axplora’s Pompey site will provide specialist purification expertise for the key protein component of CER-001.  Partnership completes Abionyx’s manufacturing partner network, supporting the program’s next regulatory and clinical stages.  Collaboration brings more than 30 years of purification expertise to a potential new treatment for LCAT deficiency and sepsis.    November 3, 2026 – Axplora has […]

Press Release

September 29, 2026

Axplora launching “Axotecan” to strengthen Global ADC supply

Independent European source of exatecan will expand choice and strengthen supply resilience for ADC developers Gram-scale material available, with validation batches targeted by the end of 2026 and GMP supply planned for late 2027 Cross-business collaboration combines Farmabios’ HPAPI expertise with Novasep CDMO’s integrated ADC capabilities   September 29th, 2026 – Axplora, a global manufacturing […]

News

September 25, 2026

Axplora celebrates 60 years of innovation at Chasse-sur-Rhône

More than 300 employees, family members and guests joined the anniversary celebration on Saturday 19 September.  Event honors six decades of expertise and the site’s continuing commitment to reliable, responsible manufacturing for customers and patients  September 25, 2026 – Axplora, a global CDMO partner for complex small molecules and antibody-drug conjugates (ADCs), has marked 60 […]

We enable our partners to fully realize their ambitions.

Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.